Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

AbbVie's Quarterly Earnings Preview: What You Need to Know

Pharma giant AbbVie is gearing up to announce its fourth-quarter results later this month and analysts expect a double-digit drop in earnings.

Barchart

2 Dividend Stocks You Can’t Miss in 2025

These companies are well-established with a solid track record of earnings growth and can cushion your portfolio with stability.

Barchart

Analyst: Sell ‘Magnificent 7’ Stocks and Buy These 3 Dividend Stocks Instead

Analysts at Miramar Capital are advising investors to sell “Magnificent 7” and instead invest in lower-valuation, dividend-paying healthcare stocks.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Highest-Yielding Dividend Kings To Buy Today

Start your New Year early by exploring high-yield Dividend Kings with decades of growth, top analyst ratings, and attractive yields for long-term investors.

Barchart

AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?

AbbVie has a lofty goal for 2025 — and a big move in cancer treatment could stoke beleaguered AbbVie stock.

Investors Business Daily

Parkinson's disease symptoms reduced by drug in late-stage trial

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose.

Fortune

Check Out What Whales Are Doing With ABBV

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 10 unusual trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Is AbbVie Stock Underperforming the Dow?

AbbVie has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Check Out What Whales Are Doing With ABBV

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

Benzinga

Pharma giant taken to court after breast implant recall

Patients allegedly exposed to a higher cancer risk from 'defective' breast implants that have now been recalled are suing a pharmaceutical firm seeking damages.

AAP

Don't Miss the Buying Opportunity in This Dividend King, Says Analyst

Leerink believes the recent selloff has made valuations attractive.

Barchart

Spotlight on AbbVie: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bearish stance on AbbVie (NYSE:ABBV).

Benzinga

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%.

Benzinga

4 Analysts Assess Enanta Pharma: What You Need To Know

In the last three months, 4 analysts have published ratings on Enanta Pharma (NASDAQ:ENTA), offering a diverse range of perspectives from bullish to bearish.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Market Whales and Their Recent Bets on ABBV Options

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie (NYSE:ABBV) revealed 13 unusual trades.

Investors Business Daily

AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback

AbbVie stock popped Friday after an analyst upgraded it on the remaining opportunity for its Cerevel takeover despite a huge misstep.

Barchart

3 Oversold Dividend Aristocrats Ready To Explode in 2025

These three companies all have one thing in common: they are all on sale.

Barchart

Stocks Settle Mostly Higher on President-Elect Trump’s Pro-Growth Promises

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.10%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%. Stocks on Monday settled mixed, with the S&P 500 and the Dow Jones Industrials...

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is This Dividend King a Buy After a Strong Q3 Report?

This might be the perfect opportunity to buy this growth and income stock at a discount.

Barchart

Stocks Rally on Optimism in President-Elect Trump’s Policies

The S&P 500 Index ($SPX ) (SPY ) today is up +0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.94%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.07%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

Barchart

S&P 500 and Dow Jones Industrials at Record Highs as the Post-Election Rally Continues

The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.19%. Stocks today are moderately higher, with the S&P 500 and the Dow Jones Industrials...

Investors Business Daily

Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

Barchart

Are Wall Street Analysts Bullish on AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Investors Business Daily

AbbVie Earns Relative Strength Rating Upgrade; Hits Key Threshold

AbbVie shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 82.

Investors Business Daily

AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter Beat

AbbVie stock jumped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.